` IPD (ImpediMed Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

IPD
vs
S&P/ASX 300

Over the past 12 months, IPD has underperformed S&P/ASX 300, delivering a return of -54% compared to the S&P/ASX 300's 2% growth.

Stocks Performance
IPD vs S&P/ASX 300

Loading

Performance Gap
IPD vs S&P/ASX 300

Loading
IPD
S&P/ASX 300
Difference

Performance By Year
IPD vs S&P/ASX 300

Loading
IPD
S&P/ASX 300
Add Stock

Competitors Performance
ImpediMed Ltd vs Peers

S&P/ASX 300
IPD
ABT
ISRG
BSX
SYK
Add Stock

ImpediMed Ltd
Glance View

Market Cap
81m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.07 AUD
Undervaluation 40%
Intrinsic Value
Price
Back to Top